Incidence of induced abortions in Peru

Antonio Bernabé-Ortiz and colleagues misleadingly assert that, although access to induced abortion services is legally restricted in Peru, the incidence of induced abortion is “as high as, or higher than, the estimated incidence in many countries where induced abortion is legal and safe.”¹ The abortion rate (the number of abortions per 1000 women of reproductive age) is greatly influenced by a number of factors, namely contraceptive behaviour and fertility rates, and thus it is not a good measure to use to evaluate the impact of the legal status of abortion on the incidence of abortions in a particular jurisdiction. The estimated total fertility rate is 2.86 in Peru; in comparison, it is 2.04 in the United States and 1.66 in the United Kingdom.² Therefore, it is not surprising that the abortion rate in Peru may be similar to the rates in the United States and United Kingdom.

The legal status of abortion may strongly affect postconceptional attitudes concerning pregnancy termination; this effect is much better described by the abortion ratio (the number of abortions per 1000 live births). Of the approximately 8660 pregnancies reported by participants in the study by Bernabé-Ortiz and colleagues, 1127 ended in induced abortions and 996 in spontaneous abortions.¹ This means that there were approximately 6538 live births and the abortion ratio was 172.3. The authors referred to a study with US data from 2001, in which there were 6.4 million pregnancies, 1.1 million spontaneous abortions and 1.3 million induced abortions.³ The corresponding abortion ratio was 325. More recent US data indicate that there were 1 206 200 abortions⁴ and 4 138 349 births in 2005.⁵ The corresponding abortion ratio was 291.5. In England and Wales, 193 737 induced abortions⁶ and 669 601 live births were registered in 2006, with a corresponding abortion ratio of 289.3.⁷ These data show that there is a lower incidence of abortion in Peru than in other countries where abortion is legal.

Renz Puccetti MD
European Medical Association Research Working Group, Pisa, Italy

Competing interests: None declared.

REFERENCES

DOI:10.1503/cmaj.1090010

Two of the authors respond:

The correct measure of the public health burden of a discrete event is its incidence: the annual per capita rate of occurrence of the event of interest in the relevant population group. As we reported, the incidence of induced abortion in Peru is as high as, or higher than, the incidence in Britain and the United States, but in Peru this practice is illegal, performed clandestinely and potentially unsafe.¹

Evaluating the impact that legal restrictions on access to induced abortion have on the rates of induced abortion in different countries requires consideration of data from many countries. Neither we nor Renzo Puccetti undertook such an analysis; our aim was to perform a detailed analysis of data from a single country.

Puccetti’s calculation does not allow for underreporting of induced abortion by participants in our study; this does not affect the British and US statistics, which are based on clinical records.¹ Nevertheless, he is probably correct in his assertion that the legal restrictions in Peru result in relatively fewer pregnancies being terminated in that country than in Britain or the United States; that is, there are more unwanted births in Peru. Indeed, Ferrando reported that the “desired fertility rate in Peru is 1.8 children; however, an average of 2.9 children are born.”²

The high incidence of induced abortion clearly indicates a high incidence of unwanted pregnancy. In our study, 22% of pregnant women (91/410) reported that the pregnancy was unwanted. Almost half of the sexually active women in our study reported that they did not use contraception; therefore, increased provision of contraception and education on safer sex could greatly reduce the rates at which induced abortions are performed. We hope that our study will increase awareness of the scale of the problem and stimulate political action to address it; there is already public support in Latin America for such action.³

Peter J. White PhD
MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College London, London, United Kingdom

Antonio Bernabé-Ortiz MD
Universidad Peruana Cayetano Heredia, Lima, Peru

Competing interests: None declared.
REFERENCES


Dengue and chikungunya in India

Sanjit Bagchi recently highlighted the surge in cases of dengue in India. It is worth noting that chikungunya, another disease borne by the *Aedes aegypti* mosquito, also poses a major health threat to large populations. The 2 diseases have similar symptoms, although hemorrhagic manifestations are relatively rare with chikungunya. Therefore, care should be taken when caring for patients suffering from either of these diseases as the diagnosis could be incorrect. Although cases of dengue are mostly seen in the northern parts of India, chikungunya is more prevalent in India’s southern states.

The control of mosquito-borne diseases in India usually involves a strategy based on that used to control the spread of malaria by *Anopheles* mosquitoes. However, unlike *Anopheles* mosquitoes, the *Aedes* mosquitoes that spread dengue and chikungunya can breed in clean as well as in dirty water, and they usually bite during the daytime.

These mosquito-borne diseases have a socio-economic impact as well. A few foreign tourists have reported symptoms of chikungunya upon their return home from tropical areas. Assuming that the number of tourists visiting tropical countries from non-endemic countries would decline owing to epidemics of these diseases, Mavalankar and colleagues reported that the loss of tourism revenue would be comparable to the estimated annual cost of preventing or treating chikungunya and dengue in these countries. Such a decline in tourism revenue would be a major setback for a country like India, which is a hotspot for tourism and where almost 80% of patients with chikungunya live below the poverty line.

Devesh V. Oberoi MBBS
General practitioner and independent researcher, Mangalore, India

Competing interests: None declared.

REFERENCES


Efficacy of pneumococcal polysaccharide vaccine

In their commentary about our meta-analysis of the efficacy of pneumococcal polysaccharide vaccine, Ross Andrews and Sarah Moberley stated that our conclusions go beyond the evidence presented and that a need exists for new trials to contribute more data, rather than repeated analyses of existing data.

Unlike the recent Cochrane review by Moberley and colleagues, our study thoroughly examined sources of heterogeneity in trial results. We found little evidence of vaccine protection in trials of higher methodologic quality for presumptive pneumonia, all-cause pneumonia and all-cause mortality. Given that the combined relative risks (RR) for these analyses are all either on the side of no protective effect or very close to 1, we do not believe that our conclusion can be described as an overstatement. The area of debate and uncertainty relates to vaccine efficacy against invasive pneumococcal disease. We found no strong evidence of efficacy (RR 0.90, 95% confidence interval [CI] 0.46–1.77) whereas the Cochrane review showed a statistically significant protective effect (RR 0.26, 95% CI 0.15–0.47). The results for invasive pneumococcal disease are greatly dependent on which studies are selected for inclusion. For example, if trials of lower quality that were not double blind (a process that Andrews and Moberley agree is worthwhile) are excluded from the Cochrane review, the effect is no longer statistically significant (RR 0.47, 95% CI 0.13–1.72). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group considers that inconsistencies in results reduce the quality of evidence.

Andrews and Moberley said that the recommendations made by the World Health Organization in its latest position paper on the use of the vaccine remained unchanged. This is not entirely correct, as in 2003 the organization recommended pneumococcal vaccination for individuals at increased risk of invasive pneumococcal disease, and in 2008 this recommendation was removed. The organization’s current position paper does not support the introduction of pneumococcal polysaccharide vaccine in resource-limited settings and suggests that priority should be given to the introduction and maintenance of pneumococcal conjugate vaccination for infants. Instead of a recommendation there is now a statement that results are consistent with a protective effect for selected outcomes in restricted groups of individuals.

Pneumococcal infections cause a large burden of disease worldwide, and control of this disease with an efficacious vaccine would be highly desirable. However, we do not think that the pneumococcal polysaccharide vaccine is the answer. After over 60 years of research on the pneumococcal polysaccharide vaccine, we might expect there to be convincing evidence of efficacy if the vaccine offered worthwhile protection. We do not recommend conducting further studies on this vaccine, as Andrews and Moberley suggest, but rather suggest exploring alternative possibilities to pneumococcal polysaccharide vaccine. Currently, the conjugate vaccine seems